National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

From the 6/4/2021 release of VAERS data:

This is VAERS ID 1261802



Case Details

VAERS ID: 1261802 (history)  
Form: Version 2.0  
Age: 61.0  
Sex: Male  
Location: South Carolina  
Vaccinated:2021-04-09
Onset:2021-04-11
   Days after vaccination:2
Submitted: 0000-00-00
Entered: 2021-04-27
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH ER8734 / 2 RA / -

Administered by: Unknown       Purchased by: ?
Symptoms: Psoriasis, Psoriatic arthropathy
SMQs:, Arthritis (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: OTEZLA
Current Illness: Psoriasis; Psoriatic arthritis
Preexisting Conditions: Medical History/Concurrent Conditions: Allergic rhinitis; Coronary artery disease; Depression; High cholesterol; Hypertension
Allergies:
Diagnostic Lab Data:
CDC Split Type: USPFIZER INC2021408109

Write-up: A flare of psoriasis (plaque, guttate, and intertriginous) and psoriatic arthritis; A flare of psoriasis (plaque, guttate, and intertriginous) and psoriatic arthritis; This is a spontaneous report from a non-contactable consumer (patient). A 61-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; solution for injection; Lot Number: ER8734) via an unspecified route of administration in the right arm on 09Apr2021 at 12:00 (at the age of 61-years-old) as a single dose for COVID-19 immunization. Medial history included HTN (hypertension), high cholesterol, CAD (coronary artery disease), depression, allergic rhinitis, all from unspecified dates and unspecified if ongoing and ongoing psoriasis and psoriatic arthritis from unspecified dates. It was unknown whether the patient was diagnosed with COVID-19 prior to vaccination. The patient had no known allergies. Concomitant medications included apremilast (OTEZLA) taken for psoriasis and psoriatic arthritis from an unspecified date and unspecified if ongoing. It was reported that no other vaccine was received in four weeks prior to the COVID-19 vaccine and it was also reported that another vaccine was reported in two weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; solution for injection; Lot Number: ER8730) via an unspecified route of administration in the right arm on 19Mar2021 at 09:00 (at the age of 61-years-old) as a single dose for COVID-19 immunization. On 11Apr2021 the patient experienced a flare of psoriasis (plaque, guttate, and intertriginous) and psoriatic arthritis. The clinical course was reported as follows: "I take Otezla for Psoriasis and Psoriatic Arthritis. I have been well controlled for over a year. On the 3rd day following the vaccine I developed a flare of psoriasis (plaque, guttate, and intertriginous) and psoriatic arthritis." Treatment was not received for the events. The clinical outcomes of the events a flare of psoriasis (plaque, guttate, and intertriginous) and psoriatic arthritis were both recovering/resolving. Since the vaccination, the patient had not been tested for COVID-19. No follow up attempts are possible. No further information is expected.


New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1261802


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166